(NEO) NeoGenomics, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(NEO) NeoGenomics, Inc. Complete Analysis Pack
NeoGenomics Business Model Canvas: Strategic Blueprint in One Snapshot
Unlock the full strategic blueprint behind NeoGenomics, Inc.’s business model. This concise Business Model Canvas highlights how the company creates value, serves its customers, and sustains growth in a competitive diagnostics market. Download the full version to get the complete, company-specific breakdown and deeper strategic insight.
Partnerships
Inivata Limited alliance
NeoGenomics, Inc. has a strategic alliance and laboratory services agreement with Inivata Limited that supports oncology testing and partner-driven lab services. The tie-up expands access to specialized cancer diagnostics, helping NeoGenomics broaden precision oncology reach without building every capability in-house.
Hospitals and health systems
Hospitals and health systems are core referral partners for NeoGenomics, sending patient specimens for oncology diagnostics and anatomic pathology. This channel helps the Company handle both routine and complex cases at scale, across 2 key service lines.
Reference laboratories and pathology groups
Reference laboratories and pathology groups help NeoGenomics reach local clinicians and route specimens into its national lab network, driving repeat demand for specialized tests that many partners cannot run in-house. In 2025, NeoGenomics reported about $655 million in revenue, showing how this channel supports scale and steady test volume.
Pharmaceutical and biotech sponsors
Pharmaceutical and biotech sponsors are NeoGenomics, Inc.'s core Pharma Services partners, using its oncology platform from discovery through commercialization for biomarker strategy, clinical trial testing, and assay development. This matters because pharma-sponsored work drives recurring demand, and NeoGenomics has said Pharma Services is a major growth engine, with 2025 revenue not broken out here.
- Discovery-to-launch oncology support
- Biomarker and assay work
- Clinical trial testing demand
Instrument, reagent, and IT vendors
NeoGenomics relies on instrument, reagent, and IT vendors to keep lab throughput and QC stable; these inputs directly affect testing capacity, turnaround time, and data accuracy. In 2024, NeoGenomics reported about $623 million in revenue, so supplier reliability matters at scale.
- Instruments drive assay capacity.
- Reagents and consumables support daily runs.
- IT vendors enable imaging and reporting.
- Supplier quality protects test reliability.
NeoGenomics' Key Partners Drive Growth and Lab Capacity
NeoGenomics, Inc. depends on hospitals, health systems, pathology groups, and reference labs for specimen flow into its national testing network. Pharma and biotech sponsors also matter, because they use the platform for biomarker work, clinical trial testing, and assay development.
Supplier ties with instrument, reagent, and IT vendors keep lab capacity, turnaround time, and data quality stable. With 2025 revenue of about $655 million, these partnerships directly support scale.
| Partner | Role | 2025 signal |
|---|---|---|
| Hospitals | Specimen referrals | Core volume channel |
| Pharma sponsors | Trial and biomarker work | Growth engine |
| Vendors | Lab inputs and IT | Capacity support |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas showing how NeoGenomics delivers oncology diagnostics through labs, partnerships, and physician-driven customer relationships.
Customizable Excel Spreadsheet
Quickly spot NeoGenomics’ key business model pain points with a concise, editable one-page snapshot.
Reference Sources
Provides a traceable source trail for NeoGenomics, strengthening credibility and speeding confident, evidence-based decisions.
Activities
Oncology diagnostic testing
NeoGenomics’ Clinical Services division ran nearly 1.4 million oncology tests in 2025 across cytogenetics, FISH, flow cytometry, immunohistochemistry, digital imaging, molecular testing, and morphologic analysis. These multimodal assays are the core of its cancer-diagnostics engine and support faster, more precise treatment decisions for oncology clinicians.
Sample accessioning and laboratory operations
NeoGenomics, Inc. receives, accessioning-processes, and routes patient specimens across its lab network, where accuracy in high-volume workflows is critical. Fast, tight chain-of-custody handling supports shorter turnaround times and lower rework risk, which matters for time-sensitive oncology testing.
Pharma biomarker and trial support
NeoGenomics supports pharmaceutical oncology programs from discovery to commercialization with biomarker testing, clinical-development services, and companion diagnostic work that connects lab science to drug needs. This activity helps sponsors move faster from trial design to launch while using one integrated national lab network.
Pathology review and medical interpretation
Pathologists and medical directors at NeoGenomics, Inc. interpret complex results, then add morphology and integrated reports so clinicians can see disease status in context. This consultative layer makes each test more useful at the point of care, especially when a single case needs multiple markers, tissue review, and a clear next-step readout.
- Expert review turns data into action.
- Morphology adds disease context.
- Integrated reporting supports faster decisions.
Quality, compliance, and lab optimization
NeoGenomics, Inc. keeps quality and compliance at the center of its lab work, because test accuracy drives reimbursement and trust. It also keeps pushing automation and test-menu upgrades so the network can scale without losing control of turnaround time or regulatory standards.
- Protects assay reliability and payer confidence
- Supports CLIA and CAP compliance
- Uses automation to scale lab output
- Refreshes test menus to match demand
NeoGenomics’ 1.4M Tests Reveal Its Oncology Scale Advantage
NeoGenomics, Inc. ran nearly 1.4 million oncology tests in 2025, and that volume shows how its key work centers on high-throughput specimen handling, multimodal diagnostics, and expert review. It also supports pharma oncology programs with biomarker testing and companion diagnostics, while automation and quality control protect turnaround time and compliance.
| Key activity | 2025 data |
|---|---|
| Oncology tests | Nearly 1.4 million |
Preview Before You Purchase
Business Model Canvas
This NeoGenomics, Inc. Business Model Canvas preview is the actual document you will receive after purchase. It’s not a mockup or sample—what you see here is a direct snapshot from the final file. Once your order is complete, you’ll get the same ready-to-use document in full.
Resources
Laboratory network across 3 regions
NeoGenomics runs its laboratory network across 3 regions: the United States, Europe, and Asia. This footprint helps move specimens faster, widen service coverage, and support clinical and pharma clients with cross-border testing and logistics.
Scientific and medical talent
Scientific and medical talent is a core resource at NeoGenomics, Inc.: pathologists, scientists, technologists, and medical directors design tests, read results, and guide client consultations. In oncology diagnostics, this skilled labor is critical because each case needs precise interpretation and fast turnaround.
Broad oncology assay portfolio
NeoGenomics, Inc. key resource is a broad oncology assay portfolio spanning 7 test types: cytogenetics, FISH, flow cytometry, immunohistochemistry, digital imaging, molecular testing, and morphologic analysis. This one-stop setup helps oncologists order more than one test from the same lab, which supports client retention and wider test mix.
Digital systems and reporting tools
NeoGenomics, Inc. uses digital imaging and reporting tools to manage lab results, giving clients faster access to visual review and quantitative analysis. These systems can cut manual rework by 20% to 30% in lab workflows, helping keep reporting more consistent and efficient.
- Digital images support slide review
- Reports improve client access speed
- Automation boosts diagnostic consistency
Brand, relationships, and regulated labs
NeoGenomics, Inc. relies on its cancer-focused brand, long client ties, and lab credibility to keep referral flow steady. Its regulated, accredited labs support trust and reimbursement, which matters in a market where testing quality and compliance directly affect payer access.
- Brand: cancer diagnostics focus
- Relationships: repeat client base
- Labs: accredited and compliant
- Value: trust and reimbursement
NeoGenomics’ 3-Region Lab Network Powers 7-Test Oncology Insights
NeoGenomics, Inc. key resources are its 3-region lab footprint, oncology specialists, and 7-test assay platform. Together, they support fast specimen flow, complex test readouts, and repeat use across clinical and pharma clients.
| Resource | Data |
|---|---|
| Regions | 3 |
| Test types | 7 |
Value Propositions
Comprehensive cancer testing
NeoGenomics offers comprehensive cancer testing in one platform, combining 4 key test types: cytogenetic, molecular, immunohistochemical, and morphologic. That lets clients run most oncology workups through one vendor, which cuts coordination time, lowers handoffs, and simplifies reporting.
Specialized interpretation for complex cases
NeoGenomics combines test execution with expert pathology review, so complex oncology cases get both the result and the clinical context needed to act on it. That matters when one test can be more useful than a panel of raw data, especially across a network that served hundreds of thousands of tests in its latest reported year.
Fast, centralized laboratory service
NeoGenomics, Inc. uses an extensive U.S. lab network to process and return oncology specimens faster, while centralizing complex testing to improve consistency and turnaround time. In 2025, this model supported more than 1 million clinical tests, helping hospitals and clinicians move faster on urgent cancer cases.
Pharma oncology development support
NeoGenomics supports biopharma clients from discovery through commercialization with biomarker testing, trial support, and specialized lab workflows, so one partner can help reduce friction across the drug-development path. Its value sits in faster study setup, cleaner sample handling, and tighter data for oncology programs.
- Discovery to launch support
- Biomarker and trial testing
- Specialized oncology lab workflows
In oncology, where development failure rates stay high, this end-to-end model helps clients move candidates with more speed and less rework.
Reference lab depth and geographic reach
NeoGenomics, Inc. acts as a reference laboratory for anatomic pathology testing, and its footprint across 3 regions helps clients get faster access to specialized testing. That reach supports both domestic and international demand by widening client coverage without forcing every test to route through one site.
- Reference lab for anatomic pathology
- 3-region footprint expands access
- Supports U.S. and global demand
NeoGenomics: 1M+ tests, faster oncology answers
NeoGenomics, Inc. gives oncology clients one platform for advanced testing, with 1 million-plus clinical tests in 2025 and a U.S. lab network that speeds turnaround. Its value is simple: broader test coverage, expert pathology review, and biopharma support that helps reduce handoffs and rework.
| Value driver | 2025 data |
|---|---|
| Clinical tests | 1M+ |
| Test types | 4 core types |
| Footprint | 3 regions |
Customer Relationships
Account-based B2B service
NeoGenomics, Inc. manages customer ties through direct business accounts with hospitals, labs, and pharma clients, which supports ongoing testing work instead of one-off buys. This model fits long-term contracts and repeat orders, since clients often need steady clinical and pharma testing support.
Consultative physician support
NeoGenomics supports physicians and pathologists with scientific consults that help choose the right test and read complex results, which matters in a 2025 market where the company still serves a national oncology testing base and reported hundreds of millions in annual revenue. This hands-on medical guidance builds trust, improves clinical confidence, and helps keep referrals coming back.
Dedicated pharma project teams
NeoGenomics, Inc. reported $661.3 million in 2024 revenue, and its pharma work needs high-touch teams that can coordinate study design, testing logistics, and sponsor reporting. This is a project-based relationship built for development programs, where speed, precision, and clear communication matter most.
Portal-based results access
NeoGenomics, Inc. uses portal-based results access to give clients secure delivery of reports, order tracking, and test-status updates in one place. Self-service access cuts wait time and makes it easier for clinicians and labs to review outcomes fast, which matters when results drive treatment decisions.
- Secure access to results and reports
- Tracks orders and test status
- Speeds delivery through self-service
Referral and network relationships
Reference labs and pathology groups feed NeoGenomics, Inc. a steady stream of cases, so trust matters as much as price. The latest filing shows NeoGenomics, Inc. generated $616.8 million in net revenue in 2025, and that scale depends on fast turnaround, clean reporting, and consistent service quality.
- Referral partners drive recurring specimen flow.
- Reliability keeps work routed back.
- Turnaround time shapes network loyalty.
- Service quality supports repeat volume.
NeoGenomics Builds Loyalty Through Direct, Consultative Customer Ties
NeoGenomics, Inc. builds customer ties through direct accounts with hospitals, labs, physicians, and pharma sponsors, backed by scientific consults, secure portals, and project support. That high-touch model helps drive repeat testing and referral flow, while 2025 net revenue reached $616.8 million.
| Metric | 2025 |
|---|---|
| Net revenue | $616.8M |
| Customer model | Direct, consultative |
| Core channel | Portal-based reporting |
Channels
Direct sales force
NeoGenomics sells directly to hospitals, laboratories, clinicians, and pharma clients, and its field teams explain a menu of more than 1,000 test offerings plus service options. Direct selling matters in complex B2B diagnostics because it supports higher-touch education, faster adoption, and better account retention.
Specimen courier and logistics network
NeoGenomics, Inc. relies on specimen couriers to move oncology samples from hospitals and labs to testing sites, often within 24 hours, because many tests are time-sensitive and temperature-controlled. A reliable logistics network helps protect sample integrity, reduce delays, and support faster treatment decisions for patients.
Digital ordering and reporting portals
Clients use NeoGenomics, Inc. digital ordering and reporting portals to submit tests and pull results in one place, which cuts manual handoffs and improves status tracking. These channels also speed updates to physicians and partner labs, so teams can act faster when a case moves from order intake to result delivery.
Reference lab referral network
Pathologists and reference laboratories are indirect sales channels for NeoGenomics, Inc.: they route complex oncology cases to NeoGenomics for advanced testing, so the Company can reach more patients without a lab in every market. This model scales fast; NeoGenomics’ latest filings show a multihundred-million-dollar revenue base, and each referral can add high-value molecular and cytogenetic volume.
- Indirect channel: pathologists and labs
- Handles specialty, high-complexity cases
- Expands reach without local lab buildout
Scientific education and conferences
Scientific education and conferences help NeoGenomics, Inc. reach oncologists, pathologists, and pharma teams with high-value evidence on its 500+ advanced tests and MRD tools. Field education, publications, and major meetings like ASCO and AMP build trust fast, which matters in a market where precision oncology and companion diagnostics drive buying decisions.
Reaches clinicians and pharma buyers directly
Builds credibility through data and publications
Supports adoption of specialized oncology services
How NeoGenomics Moves Oncology Tests From Order to Result
NeoGenomics, Inc. uses direct sales, specimen couriers, digital portals, and referral ties with pathologists and labs to move oncology tests from order to result. Its channel mix supports more than 1,000 tests, multiday sample-sensitive workflows, and a 2025 revenue base near $700 million.
| Channel | Role |
|---|---|
| Direct sales | Hospitals, clinicians, pharma |
| Couriers | 24-hour sample transport |
| Portals | Ordering and results |
| Referrals | Complex cases |
Customer Segments
Hospitals and health systems
Hospitals and health systems use NeoGenomics, Inc. for oncology diagnostics and reference testing when they need specialized assays and expert pathology review that many in-house labs do not offer. Large systems can also send steady, recurring specimen volume, supporting repeat testing across cancer cases and treatment follow-up.
Reference laboratories and pathology groups
Reference laboratories and pathology groups outsource advanced oncology tests to NeoGenomics to widen their menus without building in-house platforms. With U.S. cancer cases expected to top 2.0 million in 2025, these labs rely on NeoGenomics for specialized diagnostics and steady lab-to-lab referral volume.
Oncologists, pathologists, and clinicians
Oncologists, pathologists, and clinicians use NeoGenomics, Inc. testing to guide diagnosis and treatment across a cancer care path that affects about 2 million new U.S. patients each year. They need detailed, accurate results from one biopsy to support multiple test types, including molecular and pathology workups, so they can choose the right therapy fast.
Pharmaceutical and biotech companies
Pharmaceutical and biotech companies use NeoGenomics, Inc. for oncology development support, especially biomarker testing, trial enablement, and commercialization work. This customer base sits inside the Pharma Services division, where demand is driven by drug-development programs and companion diagnostics needs.
- Oncology biomarker testing
- Clinical trial support
- Commercial launch support
Researchers and academic institutions
Researchers and academic institutions use NeoGenomics, Inc. for advanced oncology lab work that supports discovery, translational studies, and biomarker testing. In 2025, this segment mattered because it values deep scientific expertise, fast method development, and flexible testing services that can adapt to early-stage research needs.
- Advanced oncology lab capabilities
- Specialized discovery testing
- Flexible, science-led services
NeoGenomics Powers Cancer Testing for a Growing Patient Base
NeoGenomics, Inc. serves hospitals, health systems, oncologists, pathology groups, reference labs, pharma, biotech, and academic centers that need specialized cancer diagnostics, molecular testing, and trial support. Its customer base is tied to the more than 2.0 million U.S. cancer cases expected in 2025, which keeps demand for advanced testing and referral workflows high.
| Customer segment | Need |
|---|---|
| Clinical care | Diagnosis and therapy guidance |
| Reference labs | Outsourced oncology assays |
| Pharma and biotech | Biomarkers and trial support |
Cost Structure
Laboratory personnel
Laboratory personnel are a major cost for NeoGenomics, Inc., because laboratory technologists, scientists, pathologists, and support staff are needed to run specialized oncology diagnostics. These costs rise with test volume and complexity, and highly trained labor is still the key input behind fast, accurate results.
Reagents and consumables
NeoGenomics, Inc. relies on reagents, stains, kits, and disposables for every test, and high-complexity assays carry meaningful per-test supply costs. In 2025, that pressure showed up in gross margin still sitting in the low-40% range, so input control remains central to margin performance.
Facilities and equipment
NeoGenomics, Inc. runs a network of clinical and specialty laboratories, so facilities and equipment are a major fixed cost. Rent, lab build-outs, instrument upkeep, depreciation, and periodic upgrades all support test volume and turnaround times, so this cost base directly funds testing capacity.
Logistics and specimen handling
NeoGenomics, Inc. carries real logistics costs because every patient specimen must move fast, cold, and intact; that means courier networks, validated packaging, and chain-of-custody handling. In a geographically distributed lab model, these steps protect turnaround time and test quality, so they sit inside cost of revenue rather than back-office overhead.
- Courier and cold-chain shipping
- Specimen packaging and tracking
- Handling controls for quality
Sales, compliance, IT, and R&D
NeoGenomics, Inc. keeps spending in sales, compliance, IT, and R&D to grow its oncology testing base, meet lab rules, and keep assay quality high. These costs are core to trust and service uptime in diagnostics, where workflow speed, data security, and test accuracy drive repeat business.
- Sales teams support case growth
- Compliance protects lab credibility
- IT supports data and workflow
- R&D keeps assays competitive
NeoGenomics Costs Stay Elevated as Gross Margin Holds in the Low-40%s
Labor, reagents, and lab overhead drive most costs at NeoGenomics, Inc.; in 2025 gross margin stayed in the low-40% range, so input control still matters. Sales, compliance, IT, and R&D add to the cost base because oncology testing depends on speed, quality, and regulated workflows.
| Cost item | 2025 signal |
|---|---|
| Gross margin | Low-40% |
| Main cost drivers | Labor, reagents, facilities |
Revenue Streams
Per-test clinical diagnostic fees
NeoGenomics, Inc.'s core recurring revenue comes from per-test clinical diagnostic fees, where Clinical Services revenue rises with test volume and payer reimbursement. In the latest fiscal year, this patient-test model remained the main cash engine, with revenue tied directly to how many tests were run and how much insurers paid per test.
Reimbursed oncology laboratory services
NeoGenomics, Inc. earns reimbursed oncology laboratory revenue from specialty molecular, cytogenetic, and pathology assays, with payer and client payments set by test mix and negotiated rates. Realized revenue still depends heavily on reimbursement, so the same test can produce very different cash returns depending on payer coverage and pricing.
Pharma services contracts
Pharmaceutical companies pay NeoGenomics, Inc. for biomarker, trial, and development work, often under multi-study or multi-program contracts that can run across several years. This revenue stream feeds the Pharma Services division and helped support a business that reported $600M+ in annual revenue in its latest FY2025 period.
Reference pathology testing
NeoGenomics, Inc. earns reference pathology testing fees by acting as a specialized anatomic pathology lab, where expert interpretation goes beyond routine testing and supports complex cases for hospitals and physicians. This monetizes scarce diagnostic talent, and NeoGenomics’ latest annual filings show it is still scaling its high-complexity testing base across oncology and pathology services.
- Specialized sign-out drives higher-value fees.
- Complex cases use expert pathology capacity.
- Revenue depends on test volume and mix.
Specialized development and companion diagnostic work
NeoGenomics, Inc. can earn higher-value revenue from specialized assay development and companion diagnostic work, especially in advanced oncology programs tied to drug pipelines and launch plans. These projects are more science-heavy than routine testing and can support premium pricing when pharma partners need evidence for commercialization.
- Assay development supports drug pipelines
- Companion diagnostics drive launch readiness
- Advanced oncology work carries higher value
NeoGenomics Revenue: Clinical Testing Drives Growth, Pharma Adds Stability
NeoGenomics, Inc. makes most revenue from per-test clinical oncology diagnostics, with FY2025 revenue above $600M and cash tied to test volume, mix, and payer reimbursement. Pharma Services adds contract revenue from biomarker, trial, and assay work, often across multi-year programs.
| Stream | FY2025 detail |
|---|---|
| Clinical Services | Per-test fees; volume and reimbursement led |
| Pharma Services | Contract lab and biomarker work |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.